# OnCo record nct06892522 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06892522/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06892522", "NCT06892522" ;
  schema:name "A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe"@en ;
  schema:description "A phase 1/2 trial of Lenalidomide, Dexamethasone, Daratumumab in multiple myeloma, run by AbbVie, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06892522/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06892522> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-06-30" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:drugs <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/mezigdomide/>, <https://onco.cc/drugs/iberdomide/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .